Patents by Inventor David Matthew Marquis

David Matthew Marquis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL-6 antibodies
    Patent number: 8623362
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: January 7, 2014
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Anti-IL-6 Antibodies, Compositions, Methods and Uses
    Publication number: 20130017208
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: June 15, 2012
    Publication date: January 17, 2013
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Anti-sclerostin antibodies
    Patent number: 8257704
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: September 4, 2012
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: 8226611
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 24, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Methods of using TGF-? 1 binding compositions
    Patent number: 8128927
    Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: March 6, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Craig Duane Dickinson, David Matthew Marquis, Ying Tang, Peter Edward Vaillancourt
  • Anti-IL-6 Antibodies, Compositions, Methods and Uses
    Publication number: 20120045453
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 23, 2012
    Inventors: YAN CHEN, DEBRA GARDNER, DAVID M. KNIGHT, MICHAEL W. LARK, BAILIN LIANG, DAVID J. SHEALY, XIAO-YU R. SONG, VEDRANA STOJANOVIC-SUSULIC, RAYMOND W. SWEET, SUSAN H. TAM, SHENG-JIUN WU, JING YANG, DAVID MATTHEW MARQUIS, ERIC MICHAEL SMITH, ALAIN PHILIPPE VASSEROT
  • Methods of treating conditions using anti-IL-6 antibodies
    Patent number: 8067003
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 29, 2011
    Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • ANTI-SCLEROSTIN ANTIBODIES
    Publication number: 20110250205
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Andrew Ihor KORYTKO, David Matthew MARQUIS, Eric Michael SMITH, Barbara Anne SWANSON
  • Anti-CXCR4 antibodies
    Patent number: 8003102
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: August 23, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Methods of treatment comprising administering an anti-sclerostin antibody
    Patent number: 7988970
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20110086027
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 14, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies
    Publication number: 20110081355
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 7, 2011
    Inventors: YAN CHEN, DEBRA GARDNER, DAVID M. KNIGHT, MICHAEL W. LARK, BAILIN LIANG, DAVID J. SHEALY, XIAO-YU R. SONG, VEDRANA STOJANOVIC-SUSULIC, RAYMOND W. SWEET, SUSAN H. TAM, SHENG-JIUN WU, JING YANG, DAVID MATTHEW MARQUIS, ERIC MICHAEL SMITH, ALAIN PHILIPPE VASSEROT
  • Humanized anti-ghrelin antibodies
    Patent number: 7901679
    Abstract: Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: David Matthew Marquis, Eric Michael Smith, Danise Rogers Subramaniam, Derrick Ryan Witcher
  • Anti-CXCR4 antibodies
    Patent number: 7892546
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Anti-IL-23 antibodies
    Patent number: 7872102
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: January 18, 2011
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot
  • Anti-IL-6 antibody nucleic acid molecules and methods
    Patent number: 7833755
    Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: November 16, 2010
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20100285005
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 11, 2010
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Anti-Sclerostin Antibodies
    Publication number: 20100221263
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-sclerostin antibodies
    Patent number: 7744874
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: RE43672
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 18, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chan, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot